Drug Profile
NIC 002
Alternative Names: Anti-nicotine immunotherapy - Cytos; Anti-nicotine virus-like particle vaccine - Cytos; CYT002-NicQβ; Immunodrug™ nicotine addiction vaccine - Cytos/Novartis; NIC002 vaccine; Nicotine-QβLatest Information Update: 02 Jun 2015
Price :
$50
*
At a glance
- Originator Cytos Biotechnology
- Developer Cytos Biotechnology; Duke University; Wake Forest University School of Medicine
- Class Smoking cessation therapies; Vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Smoking withdrawal